Saturday 31 October 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.
186.38
11.98
+6.87%
Follow AZN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
28.13 | 29.38 | 26.58 | 24.64 |
+8 more quarters Free account |
P/S ratio |
4.79 | 5.05 | 4.63 | 3.99 | |
P/FCF ratio |
46.94 | 38.48 | 30.83 | 23.93 | |
P/Operating CF |
102.65 | 90.95 | 116.08 | 45.16 | |
P/B ratio |
5.84 | 6.45 | 5.58 | 5.04 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.19 | 5.46 | 5.00 | 4.38 | |
EV/EBITDA |
15.67 | 16.38 | 15.09 | 13.15 | |
EV/Operating CF |
23.25 | 23.19 | 20.16 | 16.81 | |
EV/FCF |
50.85 | 41.54 | 33.32 | 26.27 | |
Quick Ratio |
0.67 | 0.70 | 0.72 | 0.69 | |
Current Ratio |
0.89 | 0.91 | 0.94 | 0.88 | |
Net Debt/EBITDA |
4.80 | 4.33 | 4.90 | 4.42 | |
Debt/Assets |
25.46% | 28.09% | 24.39% | 26.97% | |
Debt/Equity |
0.59 | 0.68 | 0.57 | 0.67 | |
Asset Turnover |
0.54 | 0.55 | 0.54 | 0.53 | |
Operating CF/Net income |
1.14 | 1.09 | 1.01 | 2.03 | |
Capex/Depreciation |
(1.55) | (1.09) | (0.82) | (1.11) | |
Interest Coverage |
7.27 | 10.80 | 6.31 | 8.26 | |
Research and Development Expense of Revenue |
26.35% | 22.84% | 24.91% | 24.11% | |
Selling, General and Administrative Expense of Revenue |
37.68% | 33.10% | 36.41% | 34.45% | |
Intangible Assets out of Total Assets |
0.51 | 0.51 | 0.52 | 0.52 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.13) | (0.12) | (0.13) | (0.17) | |
Graham Number |
70.19 | 67.97 | 68.35 | 63.61 | |
Earnings Yield |
3.56% | 3.40% | 3.76% | 4.06% | |
Free Cash Flow Yield |
2.13% | 2.60% | 3.24% | 4.18% | |
Revenue per Share |
9.92 | 9.87 | 10.01 | 9.79 | |
Operating CF per Share |
1.85 | 2.17 | 1.51 | 3.31 | |
Capex per Share |
(1.92) | (0.96) | (0.80) | (1.11) | |
Free Cash Flow per Share |
(0.07) | 1.21 | 0.71 | 2.20 | |
Cash per Share |
3.25 | 4.97 | 3.76 | 5.28 | |
Shareholders Equity per Share |
32.48 | 30.59 | 31.45 | 29.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
32.48 | 30.59 | 31.45 | 29.64 | |
Free Cash Flow |
(116.00) | 1,874.00 | 1,098.00 | 3,409.00 | |
Working Capital |
(3,588.00) | (2,957.00) | (1,894.00) | (4,114.00) | |
Capital Expenditures |
(2,981.00) | (1,485.00) | (1,244.00) | (1,725.00) | |
Net Current Asset Value |
(37,498.00) | (37,018.00) | (36,632.00) | (38,545.00) | |
EV/EBIT |
22.80 | 23.04 | 21.38 | 19.89 | |
Capex to Sales |
0.19 | 0.10 | 0.08 | 0.11 | |
Price to Operating Income |
21.05 | 21.34 | 19.78 | 18.11 | |
| Other line items | |||||
Average Receivables |
15,579.00 | 14,990.00 | 15,583.00 | 14,350.00 | |
Average Payables |
23,439.50 | 22,524.50 | 23,872.50 | 23,356.00 | |
Average Inventory |
6,699.50 | 6,227.00 | 5,922.50 | 6,127.50 | |
Average Assets |
114,127.50 | 110,134.00 | 109,054.50 | 109,689.00 | |
Average Common Equity |
47,590.00 | 44,257.50 | 44,795.00 | 43,388.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026